Considering antiplatelet drugs, preclinical data suggest that cyclooxygenase (COX) driven prostaglandin E2 (PGE2) might promote tumor immune escape and regulate PD-L1 expression within the tumor microenvironment [21,22,23,24]. This evidence concerns the gene CD274 and neoplasm.